Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted

Stock News01-08

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., recently had a new drug registration application for Succinate Furutinib Capsules (Project Code: SAF-189; Application Classification: Chemical Drug Category 1) accepted by the National Medical Products Administration. The application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This new drug is an innovative small-molecule chemical drug. In addition to the current application, as of the announcement date (January 8, 2026), a Phase II clinical study for another indication, non-small cell lung cancer (ROS1+), has been completed within mainland China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168579641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168579641","market":"us","top_or_hot":-1,"title":"Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted","media":"Stock News","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., recently had a new drug registration application for Succinate Furutinib Capsules (Project Code: SAF-189; Application Classification: Chemical Drug Category 1) accepted by the National Medical Products Administration. The application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This new drug is an innovative small-molecule chemical drug. In addition to the current application, as of the announcement date (January 8, 2026), a Phase II clinical study for another indication, non-small cell lung cancer (ROS1+), has been completed within mainland China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma's (600196.SH) Controlled Subsidiary Has Drug Registration Application Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-08 17:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., recently had a new drug registration application for Succinate Furutinib Capsules (Project Code: SAF-189; Application Classification: Chemical Drug Category 1) accepted by the National Medical Products Administration. The application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This new drug is an innovative small-molecule chemical drug. In addition to the current application, as of the announcement date (January 8, 2026), a Phase II clinical study for another indication, non-small cell lung cancer (ROS1+), has been completed within mainland China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1168579641","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168579641","pubTimestamp":1767864984,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., recently had a new drug registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","BK0188":"融资融券","BK0096":"民营医院","BK1191":"制药","BK1515":"抗疫概念","BK1593":"医美概念股","BK0012":"证金概念","02196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"复星医药（600196.SH）控股子公司药品注册申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH) announced that its controlled subsidiary, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., recently had a new drug registration application for Succinate Furutinib Capsules (Project Code: SAF-189; Application Classification: Chemical Drug Category 1) accepted by the National Medical Products Administration. The application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This new drug is an innovative small-molecule chemical drug. In addition to the current application, as of the announcement date (January 8, 2026), a Phase II clinical study for another indication, non-small cell lung cancer (ROS1+), has been completed within mainland China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168579641","isCrawlerRequest":true}